{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'For all subjects enrolled in the study, the source documentation record will be transcribed onto', 'the eCRF.', '9.5.7.2 Day 1/Baseline', 'On Day 1, subjects will return to the clinic for Baseline assessments, randomization, and the first', 'dose of study drug.', 'Perform review of inclusion/exclusion criteria.', 'Review medical history.', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbAlc) analysis (see Section 9.5.5.7 for details concerning test results and study', 'participation).', 'Collect predose blood samples for immunogenicity testing.', 'Collect predose blood samples for biomarker analyses.', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Enquire about signs and symptoms within previous 2 weeks and concomitant', 'medications.', 'Perform predose physical and ophthalmic examinations.', 'Perform predose 12-lead ECG.', 'Perform predose Baseline efficacy assessments (CAS, Clinical Measures of Severity', 'including proptosis, diplopia and motility restriction). Proptosis and CAS may not', 'decrease > 2 mm/points in the study eye from Screening to be eligible for enrollment.', 'Administer the predose GO-QoL questionnaire.', 'Contact IWRS to obtain randomization number in order for the unmasked pharmacy to', 'receive study drug dosing information.', 'Monitor vital signs prior to and at the end of the infusion. Additional vital sign', 'monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.5.4 for details).', 'Collect blood samples for PK analyses prior to and at the end of the infusion.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 93 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Administer the first dose of study drug and record date, volume and rate of infusion, and', 'start/stop times of dosing.', 'Subjects will be discharged from the study center after all of the Study Day 1 procedures have', 'been completed and will be contacted the following day to enquire about AEs and concomitant', 'medication use.', '9.5.7.3 Week 1', 'Collect blood samples for hematology and glucose testing (see Section 9.5.5.7 for details', 'concerning test results and study participation).', 'Collect blood sample for PK analyses. Record date/time of sample collection.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Enquire about AEs and concomitant medication use.', 'Subjects will be released from the study center after all of the visit procedures have been', 'completed and instructed to return to the clinic at Week 3.', '9.5.7.4 Week 3', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbAlc) analysis (see Section 9.5.5.7 for details concerning test results and study', 'participation).', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Collect predose blood sample for immunogenicity testing.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform predose 12-lead ECG.', 'Monitor vital signs prior to and at the end of the infusion. Additional vital sign', 'monitoring may be performed in the event of infusion-associated AEs (see Section', '9.5.5.4 for details).', 'Collect blood samples for PK analyses prior to and at the end of the infusion.', 'Contact IWRS to obtain study medication vial assignment and to determine the volume', 'of study drug to be administered.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 94 of 117']\n\n###\n\n", "completion": "END"}